radequinil

Small moleculeexperimental

Radequinil is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed. — Wikipedia

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 2006 (NCT00359944)

Timeline

2000s

Jan 1, 2006
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Alzheimer Disease · Phase 2

Mechanism of action

GABA-A receptor; anion channelINVERSE AGONIST
GABA-A receptor; anion channel inverse agonist
Partial inverese agonist.
Benzodiazepine site

Chemistry & pharmacology

Loading structure…

SMILES

COc1cccc(-c2nccc3[nH]c(=O)c(-c4noc(C)n4)cc23)c1

Mol. weight: 334.34 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaRadequinil ↗
ChEMBLCHEMBL2107801 ↗

Also known as

5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-1,2-dihydro-1,6-naphthyridine
ac3933
ac 3933
ac-3933
ac-3933
ac-3933
ac-3933
ave-3933
ave-3933
radequinil
radequinil
resequinil
resequinil
sx-3933
sx-3933

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00359944	Phase 2	Feb 1, 2006	Sunovion

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Sunovion	For profit	1	1	1	2006

1 organizations

Page 1 / 1